Lead Sponsor

Hanmi Pharmaceutical Company Limited

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

No

•Aged over 19 years
•Signed informed consent
•At visit 1, LDL-C ≤ 250mg/dL and Triglyceride \< 400 mg/dL
•After 4 weeks more TLC, At visit2, LDL-C ≤ 250mg/dL, Triglyceride \< 400 mg/dL and satisfied criteria according to Risk of cardiovascular disease

•Current or past history of hypersensitivity to HMG-CoA reductase inhibitors and component of Ezetimibe
•Has an active liver disease and severe liver disorder (continous elevation of AST, ALT level or exceeds more than 3 times of normal upper limit)
•Has a severe renal failure and kidney injury (Creatinine level exceeds more than 2 times of normal upper limit)
•CK level exceeds more than 5 times of normal upper limit
•Uncontrolled hypertension patient (SBP≥ 180 mmHg or DBP ≥ 110 mmHg)
•Uncontrolled diabetes mellitus patient (HbA1c ≥ 9%)
•Uncontrolled malfunctional thyroidism (or at pre-visit 2, TSH level exceeds more than 1.5 times of normal upper limit)

Related studies

NCT06314919 · Primary Hypercholesterolemia, Mixed Dyslipidemia

NCT06568471 · Hypercholesterolemia, Dyslipidemias, and more

NCT05399992 · Primary Hypercholesterolemia, Mixed Dyslipidemia

NCT07441317 · Primary Hypercholesterolemia or Mixed Hyperlipidemia

NCT07444086 · Primary Hypercholesterolemia or Mixed Hyperlipidemia

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia